IP Library Granted Patent US 7,371,895
Granted Patent B2
US 7,371,895 · App. 11/263,821 · Granted May 13, 2008

Salt forms of poorly soluble probucol esters and ethers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,371,895
App. No.
11/263,821
Granted
May 13, 2008
Kind
B2
Abstract

Organic amine salts of compounds of the formula: and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

Claims (40)

1. A method for the treatment of rheumatoid arthritis, comprising administering to a host in need thereof a pharmaceutical composition comprising a compound of the formula:

wherein:

R 1 and R 2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is (CH 2 ) 0-5 ; when R 1 and R 2 taken together form a carbonyl, Y is (CH 2 ) 1-5 ;

together with meglumine and a pharmaceutically acceptable carrier.

2. A method for the treatment of atherosclerosis, comprising administering to a host in need thereof a pharmaceutical composition comprising a compound of the formula:

wherein:

R 1 and R 2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is (CH 2 ) 0-5 ; when R 1 and R 2 taken together form a carbonyl, Y is (CH 2 ) 1-5 ;

together with meglumine and a pharmaceutically acceptable carrier.

3. A method for treatment of hypercholesterolemia, comprising administering to a host in need thereof a pharmaceutical composition comprising a compound of the formula:

wherein:

R 1 and R 2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is (CH 2 ) 0-5 ; when R 1 and R 2 taken together form a carbonyl, Y is (CH 2 ) 1-5 ;

together with meglumine and a pharmaceutically acceptable carrier.

4. A method for treatment of hyperlipidemia, comprising administering to a host in need thereof a pharmaceutical composition comprising a compound of the formula:

wherein:

R 1 and R 2 are independently hydrogen or alkyl or taken together to form a carbonyl; and

Y is (CH 2 ) 0-5 ; when R 1 and R 2 taken together form a carbonyl, Y is (CH 2 ) 1-5 ;

together with meglumine and a pharmaceutically acceptable carrier.

5. The method of claim 1 , wherein R 1 and R 2 are taken together to form a carbonyl.

6. The method of claim 5 , wherein Y is (CH 2 ) 2 .

7. The method of claim 1 , wherein R 1 and R 2 are each hydrogen.

8. The method of claim 7 , wherein Y is (CH 2 ) 0 .

9. The method of claim 7 , wherein Y is (CH 2 ) 2 .

10. The method of claim 2 , wherein R 1 and R 2 are taken together to form a carbonyl.

11. The method of claim 10 , wherein Y is (CH 2 ) 2 .

12. The method of claim 2 , wherein R 1 and R 2 are each hydrogen.

13. The method of claim 12 , wherein Y is (CH 2 ) 0 .

14. The method of claim 12 , wherein Y is (CH 2 ) 2 .

15. The method of claim 3 , wherein R 1 and R 2 are taken together to form a carbonyl.

16. The method of claim 15 , wherein Y is (CH 2 ) 2 .

17. The method of claim 3 , wherein R 1 and R 2 are each hydrogen.

18. The method of claim 17 , wherein Y is (CH 2 ) 0 .

19. The method of claim 17 , wherein Y is (CH 2 ) 2 .

20. The method of claim 4 , wherein R 1 and R 2 are taken together to form a carbonyl.

21. The method of claim 20 , wherein Y is (CH 2 ) 2 .

22. The method of claim 4 , wherein R 1 and R 2 are each hydrogen.

23. The method of claim 22 , wherein Y is (CH 2 ) 0 .

24. The method of claim 22 , wherein Y is (CH 2 ) 2 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: ATHEROGENICS, INC.
To: CRABTREE ACQUISITION CO, LLC
Reel/Frame 024933/0616 →
CHANGE OF NAME Recorded Sep 3, 2010
From: CRABTREE ACQUISITION CO, LLC
To: SALUTRIA PHARMACEUTICALS LLC
Reel/Frame 024933/0651 →